MedTrace Logo

Validation of a Kinetic Model of Erlotinib

NCT02904850 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2016-09-19

No results posted yet for this study

Summary

Several arguments are in favor of a therapeutic monitoring for the erlotinib, therefore, a pharmacokinetic (PK) has been prepared using data from the literature. This model must be validated at concentrations achieved in practice. This is a preliminary study before the implementation of a randomized trial confirming the therapeutic monitoring of erlotinib through this model.

Conditions

Interventions

BIOLOGICAL

group of patients

Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Principal Investigators

  • Anne Elisabeth QUOIX · Service Pneumologie Hôpitaux Universitaires Strasbourg 67 091 STRASBOURG cedex

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02904850 on ClinicalTrials.gov